Oncolix, Inc. Expands Board of Directors with New Appointment
December 04 2017 - 6:30AM
Oncolix, Inc. (OTC PINK:ONCX) (the “Company”), a biotechnology
company focused on gynecological cancers, announced the appointment
of John W. Holaday, Ph.D., to the Company’s Board of Directors as
an independent board member. The appointment brings the total size
of the Board to four members, two of whom are independent, which
fulfills an OTC-QB listing requirement.
“As an accomplished CEO of several
biopharmaceutical companies, Dr. Holaday has an extensive track
record of successfully leading his companies from the ground stages
of preclinical research and clinical trials all the way through to
product launches,” said Michael T. Redman, president and chief
executive officer of Oncolix. “His expertise greatly expands
Oncolix’s capabilities in developing Prolanta™ for ovarian cancer
through clinical trials as well as for future indications and
additions to the pipeline. In addition, with this appointment, we
have now fulfilled OTC-QB requirements and expect to uplist
soon.”
Dr. Holaday has a track record of
accomplishments as a senior executive at several growing
biopharmaceutical companies. Most recently, until his retirement in
2014, Dr. Holaday was co-founder, chief executive officer, managing
director and board member of QRxPharma, a specialty pharmaceutical
company headquartered in Sydney, Australia, where he directed the
development and NDA submission of a better-tolerated opioid. Prior
to founding QRx in 2007, he was co-founder of the
technology-focused Harvest Bank of Maryland and co-founder and
chief executive officer of EntreMed, Inc., a pioneering
anti-angiogenesis company focused on oncology. He co-founded
MaxCyte, a flow electroporation company. Prior to that, he was
co-founder and executive vice president of Research and Development
at Medicis Pharmaceutical Corp., a dermatology company acquired by
Valeant Pharmaceuticals in 2012 for $2.6B. He is currently a board
member for several biopharmaceutical companies and non-profit
organizations. He earned his B.S. and M.S. from the University of
Alabama, and his Ph.D. in Pharmacology from the University of
California, San Francisco School of Medicine. He holds over 90
patents and has published over 230 scientific articles, book
chapters and four books. He served as Chair of the BioAlliance of
the Tech Council of Maryland. In 2006, he was named to the Ernst
& Young’s Entrepreneur of the Year Hall of Fame.
“Oncolix is a very promising emerging
biopharmaceutical company with a differentiated but overlooked
oncology asset in Prolanta,” said Dr. Holaday. “Ovarian cancer
still remains the leading cause of death among women with
gynecological cancers and fourth most common cause of
cancer-related deaths in women in the U.S. There are currently no
effective treatment options. Early results from the first clinical
trial are promising. It could also be developed for other cancers
such as breast and prostate. I look forward to working with Michael
to support the continued development of Prolanta™, other future
pipeline drug candidates and expansion of the company.”
About Oncolix
Oncolix is a clinical-stage biotechnology
company developing Prolanta™ for the treatment of ovarian, uterine,
breast and other cancers. The Company has a US FDA-cleared IND to
commence human testing of Prolanta™ in its first indication, the
treatment of ovarian cancer. This Phase 1 clinical trial is
currently in progress. Prolanta™ is a prolactin receptor antagonist
(or blocker) that has demonstrated efficacy in xenograft models
through a unique mechanism of action, autophagy. In addition to
ovarian cancer, there is strong preclinical evidence Prolanta™ may
be effective in breast, prostate and other cancers. In the current
Phase 1 dose-escalation safety trial for the treatment of ovarian
cancer, to date there have been no observed serious adverse events
and no dose-limiting toxicities. The FDA has approved the
designation of Prolanta™ as an Orphan Drug for the treatment of
ovarian cancer, which may result in reduced filing fees (currently
$2 million), federal tax credits and marketing exclusivity.
Corporate contact:Michael RedmanP: 281-402-3167E:
mredman@oncolixbio.com
Investor contact:The Ruth GroupRobert FlammP: 646-536-7017E:
rflamm@theruthgroup.com